- Home
- DEA vs ARQT Comparison
DEA vs ARQT Comparison
Compare DEA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- ARQT
- Stock Information
- Founded
- DEA 2011
- ARQT 2016
- Country
- DEA United States
- ARQT United States
- Employees
- DEA N/A
- ARQT N/A
- Industry
- DEA Real Estate Investment Trusts
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- ARQT Health Care
- Exchange
- DEA Nasdaq
- ARQT Nasdaq
- Market Cap
- DEA 1.4B
- ARQT 1.1B
- IPO Year
- DEA 2015
- ARQT 2020
- Fundamental
- Price
- DEA $13.29
- ARQT $10.02
- Analyst Decision
- DEA Hold
- ARQT Buy
- Analyst Count
- DEA 1
- ARQT 6
- Target Price
- DEA $14.00
- ARQT $14.40
- AVG Volume (30 Days)
- DEA 790.1K
- ARQT 2.0M
- Earning Date
- DEA 10-29-2024
- ARQT 11-01-2024
- Dividend Yield
- DEA 7.95%
- ARQT N/A
- EPS Growth
- DEA N/A
- ARQT N/A
- EPS
- DEA 0.19
- ARQT N/A
- Revenue
- DEA $299,125,000.00
- ARQT $132,062,000.00
- Revenue This Year
- DEA N/A
- ARQT $185.11
- Revenue Next Year
- DEA $5.24
- ARQT $48.43
- P/E Ratio
- DEA $71.77
- ARQT N/A
- Revenue Growth
- DEA 1.10
- ARQT 1032.90
- 52 Week Low
- DEA $10.27
- ARQT $1.76
- 52 Week High
- DEA $14.36
- ARQT $13.17
- Technical
- Relative Strength Index (RSI)
- DEA 42.53
- ARQT 51.65
- Support Level
- DEA $13.39
- ARQT $9.04
- Resistance Level
- DEA $13.62
- ARQT $10.67
- Average True Range (ATR)
- DEA 0.19
- ARQT 0.66
- MACD
- DEA -0.04
- ARQT 0.00
- Stochastic Oscillator
- DEA 9.09
- ARQT 46.30
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.